drugset / Trial / NCT04356118
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis
Timeline
- Start
- 2020-06
- Primary completion
- 2023-06
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human endostatin | Protein / enzyme biologic | 7.5 mg/m2 | — |
| Background | Afatinib | Small molecule | — | — |
| Background | Alectinib | Small molecule | — | — |
| Background | Ceritinib | Small molecule | — | — |
| Background | Crizotinib | Small molecule | — | — |
| Background | Erlotinib | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | Intrathecal |
| Background | Osimertinib | Small molecule | — | — |
| Background | Vemurafenib | Small molecule | — | — |